Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamphetamine for obesity
ACTRN12625000764437Phase 3Not yet recruiting
- Sponsor
- Nepean Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Dexamphetamine with Placebo (2 arms). Primary endpoint: Change in weight. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
dextroamphetamine
03
Conditions
obesity
Beyond the preview
Go deeper on ACTRN12625000764437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000764437.